Bioscience Association Manitoba Applauds Government Action to Advance Bioscience Research and Clinical Trials in Manitoba
'For too long, the process of moving innovative research into real-world care has taken longer in Manitoba than in other jurisdictions,' said Andrea Ladouceur, President & CEO of BAM. 'Both the new Manitoba Clinical Trials Office and RITHIM are key pieces of the puzzle that will help connect research to our ecosystem and shorten timelines and enables research to get where it's needed, into the lives of Manitobans.'
Manitoba has led with action on the top 2 recommendations from the Manitoba Clinical Trials Working Group. The first is to create a Clinical Trials office to champion connections between researcher and resources and the second is to create a timebound standardized processes.
BAM was honoured to co-chair this Working Group over the past 10 months developing recommendations to improve how research is conducted in the province.
The new Manitoba Clinical Trials Office, announced by Honourable Jamie Moses, Minister of Business, Mining, Trade, and Job Creation, will help champion Manitoba as a destination for world-class clinical research. RITHIM will also help shorten process timelines. Learn more at https://biomb.ca/manitoba-clinical-trails/.
'Clinical trials are essential to getting new, innovative medicines into our healthcare system,' noted Ladouceur. 'Canada uses only about 20 per cent of the innovative medicines available in other G7 countries. Manitoba can and should lead the way in changing that.'
The bioscience sector contributes approximately 7 per cent of Manitoba's GDP, with medicine ranked as the province's top export. Manitoba is home to a growing hub of companies like Bausch Health, Pfizer, Cytophage Technologies, Emergent, Kane Biotech, and Dynacare, which are developing solutions that help patients return to healthier lives.
'Our members are leaders in how we heal, feed, and fuel the world,' said Ladouceur. 'But innovation only matters if it reaches people. Many patients can't wait for life-saving treatments. That's why we need to continuously improve how we move research from the lab into people's lives,' noted Andrea.
With this announcement, BAM sees Manitoba taking a strong step forward toward a more coordinated, responsive, and globally competitive research environment.
'We're proud to support this important milestone,' added Ladouceur. 'Manitoba is the right place for research to thrive with strong values around inclusivity, a commitment to quality, and a collaborative mindset. We look forward to what comes next.'
For more information about this announcement, visit https://news.gov.mb.ca/news/index.html?item=69639&posted=2025-07-02.
Bioscience Association Manitoba (BAM) is a not-for-profit industry association that enables commercial success for bioscience companies in Manitoba by acting as a catalyst for innovation, leading with one unified voice for all bioscience advancement and growth, and supporting a future-focused workforce.
Learn more about Bioscience Association Manitoba: https://biomb.ca/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
18 hours ago
- Business Wire
Game-Changing HSA Reforms Just Passed—Here's What It Means for Healthcare
SAN FRANCISCO--(BUSINESS WIRE)--Today, Lively, Inc. marks the signature of the 'One Big Beautiful Bill' (OBBB) into law, a major bill that expands access and flexibility for Health Savings Accounts (HSAs). Under the new law, millions of Americans enrolled in Bronze or Catastrophic ACA plans are now eligible to contribute to HSAs starting January 1, 2026, and key innovations like telehealth services and Direct Primary Care are officially HSA-qualified expenses. Game-Changing HSA Reforms Just Passed—Here's What It Means for Healthcare: Landmark legislation enables HSA use with Bronze/Catastrophic ACA plans, telehealth, and direct primary care—bringing healthcare savings into the modern era. Share Lively, a top-rated health and lifestyle benefits platform* known for building the modern Health Savings Account (HSA), is uniquely positioned to support individuals, employers, and brokers navigating this new era. Lively's platform already connects with over 95% of U.S. health plans and integrates seamlessly with Direct Primary Care models and virtual-first providers. 'In a world of rising out-of-pocket costs, HSAs are the most powerful way to take control of US consumer healthcare finances. This isn't just a policy shift—it's a redefinition of how Americans can save, spend, and stay healthy," said Alex Cyriac, CEO and co-founder of Lively. 'At Lively, we've built a platform that's flexible, intelligent, and ready for this next generation of benefits.' What's Changing: HSA Eligibility Opens for Millions of Americans: Enrollees in Bronze and Catastrophic ACA plans are now eligible and can contribute to HSAs. Modern Care Models Included: HSA funds can be used for Direct Primary Care arrangements. Telehealth Flexibility Made Permanent: First-dollar coverage for telehealth services no longer disqualifies HSA status. How Lively Helps: No Hidden Fees - Your healthcare shouldn't come at a hidden cost — Lively HSAs are free for individuals and families. Get Started in Minutes: Confirm your eligibility and open an HSA account instantly. Smart Claim Sync: Automatically syncs with employee health plan data, including high-deductible, Bronze, and Catastrophic plans. Built for Innovation: Already supports virtual-first, Direct Primary Care (DPC), and hybrid health plan designs. About Lively Lively is the health and lifestyle benefits provider that gets it right. Our solutions are designed to take the guesswork out of managing benefits and drive efficiency for HR teams. Our innovative platform combines robust features with unparalleled service, to make maximizing your benefits as simple as it should be. Lively currently offers HSA, FSA, HRA, COBRA, Direct Bill, Commuter, Lifestyle Spending Accounts, and Medical Travel Accounts.
Business Wire
a day ago
- Business Wire
Haleon Breaks Ground on new £130m Global Oral Health Innovation Centre
LONDON--(BUSINESS WIRE)--This week, Haleon, a global leader in consumer health and maker of leading brands such as Sensodyne, parodontax and Polident, broke ground on its new Global Oral Health Innovation Centre in Weybridge, Surrey. This state-of-the-art facility will enhance Haleon's science capabilities, accelerate innovation, and serve as a centre of excellence for global oral health research. The groundbreaking ceremony, attended by UK Minister Baroness Jones, marks an important step in Haleon's ambition to reach one billion more consumers by 2030, by strengthening its oral health R&D capabilities to put health in more hands globally. Set to become the R&D epicentre for Haleon's oral health portfolio, the centre will be a dynamic hub for pioneering research, product innovation, commercial and supply chain excellence, and cross-functional collaboration. Equipped with the latest technology and global expertise, the centre will feature a cutting-edge digital immersive room designed to unlock value at pace through real-time collaboration with Haleon's manufacturing site in Levice. At the heart of the building, the atrium will create a vibrant hub for teamwork and co-creation, bringing leading expertise together to develop solutions that address unmet oral health needs for consumers around the world. Designed with sustainability at its core, the site has recently achieved a BREEAM® Outstanding rating, recognising its exceptional commitment to sustainability at Phase 1 in the design stage. Franck Riot, Chief R&D Officer, Haleon, said:" We are excited to break ground on our Global Oral Health Innovation Centre - a major investment reflecting our commitment to advancing science and innovation. This powerhouse for oral health research will strengthen Haleon's R&D capabilities and accelerate the development of cutting-edge solutions to meet the evolving oral health needs of consumers around the world. ' Chancellor of the Exchequer, Rachel Reeves MP, said: 'This exciting milestone is another demonstration of the strength of the UK life sciences sector, a key pillar to our Industrial Strategy. Under this government Britain is open for business, and through our Plan for Change we're delivering more investment, more jobs and more money in people's pockets.' UK Minister for Technology, Baroness Jones, said: 'Haleon is breaking ground on a new centre that will place the UK at the forefront of innovation to improve everyone's oral health - which we know is important to our wider health, and to children's development. This centre, and the substantial investment behind it, is proof that the UK's world-leading life sciences sector is the place to be to grow businesses and work on fresh ideas to transform healthcare. Leveraging these strengths will lead to the long-term economic growth that will help us deliver on our Plan for Change.' Jayant Singh, Global Category Lead, Oral Health, Haleon, said:" With oral diseases affecting nearly half the world's population, this marks an exciting step forward in our mission to put health in more hands for millions across the world. This centre will play a key role in harnessing the full potential of science and innovation across our oral health portfolio. ' About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
Associated Press
a day ago
- Associated Press
R&D Investments Fuel Next-Gen Immunomodulator Development Amid Patent Expiry
DUBLIN--(BUSINESS WIRE)--Jul 4, 2025-- The 'Immunomodulator Therapeutics Market, Global, 2024-2030" report has been added to offering. Revenue estimate for the base year 2024 is $93 billion with a CAGR of 9.0% for the study period 2024-2030. This research service offers a comprehensive analysis of the global immunomodulator therapeutics market, specifically targeting inflammatory disorders in the immunology, gastrointestinal (GI), and dermatology segments. The report defines this market through products designed to modify and regulate pathological immune responses, either by inhibiting or suppressing them. It categorizes the market by modality and key indications, providing a 6-year revenue forecast for global immunomodulator prescription drugs, alongside an analysis of key industry participants. The geographic scope encompasses North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and Latin America (LATAM), with regional revenue share estimates presented on a best-effort basis. The report also discusses prevalent and emerging business models, analyzes trends in market access and reimbursement for immunomodulator therapies, and offers competitive assessments and revenue share analyses. It examines the factors driving and restraining growth in this space, offering insights into drug development trends, partnerships, and the investment landscape. The report highlights key companies pioneering disruptive virtual care technologies and adjunctive therapies for effective disease management. Based on clinical needs, technological advancements, business models, and competitive dynamics, the report identifies the growth opportunities emerging from this space for market players and stakeholders to leverage. The base year is 2024, and the forecast period is from 2025 to 2030. Growth Drivers Rising Prevalence of Autoimmune and Inflammatory Diseases Increasing prevalence of diseases like lupus, RA, Crohn's disease, and psoriasis is driving demand for immunomodulators like tumor necrosis factor (TNF) inhibitors (e.g., Humira, Remicade) and JAK inhibitors (e.g., Xeljanz). The rapidly aging global population is more susceptible to chronic autoimmune conditions. It is further bolstering demand for treatments tailored to older adults, such as more tolerable biologics. Biotech Advancements Innovations in biotech platforms and advanced modalities such as CGT, bispecific antibodies, and RNA therapies are enhancing the efficacy and safety profiles of immunomodulators and driving the development of next-gen targeted therapies. Carisma Therapeutics Inc. and Moderna, Inc. have collaborated to use Carisma's proprietary CAR-M technology and Moderna's mRNA/lipid nanoparticles (LNP) platform to develop a macrophage engineering approach for autoimmune diseases. Growing Investment in R&D Increased funding from both public and private sectors is accelerating R&D efforts for discovering new therapies and improving existing ones. The NIH allocates significant funding for research on immunomodulatory therapies, fostering innovation. An increasing number of M&A deals demonstrate a growing focus on immunology by big pharma. Success in Oncology and Expanding Applications The success of immunotherapies in oncology has raised awareness and acceptance of similar approaches in treating autoimmune and inflammatory diseases. For example, Roche's Gazyva/Gazyvaro (obinutuzumab), approved in 100 nations for several lymphoma types, is being investigated in the Phase III REGISTRY trial for lupus nephritis. Growth Restraints Immunomodulator Therapeutics: Growth Restraints, Global, 2025-2030 Stringent Regulatory Processes: Stringent regulatory processes for immunomodulatory treatment approval or the development of novel mechanisms of action, globally, can cause delays in market access and raise development expenses for pharmaceutical companies. Moreover, inadequate reimbursement/insurance coverage globally may deter wide-scale adoption, especially in public health systems or regions with limited healthcare resources. Inadequate coverage of high-cost new drugs would increase the expenses of managing long-term conditions, impacting patient compliance and market growth. Potential Adverse Effects and Safety Concerns: Immunomodulators may have serious adverse effects, such as an elevated risk of infections and autoimmune responses. For example, checkpoint inhibitor use in autoimmune disease is linked to immune-related side effects that need to be carefully managed. Adverse outcomes and safety risks may lead to regulatory actions such as market recalls, limited prescriptions, and reduced patient confidence, challenging market uptake. Patent Expiry: Expiry of blockbuster drug patents is leading to the introduction of biosimilars and generic versions, intensifying market competition, resulting in price erosions, and leading to a loss of sales revenue for branded products. For example, AbbVie's blockbuster Humira, approved for several autoimmune conditions like RA, psoriasis, Crohn's disease, and ankylosing spondylitis, started facing biosimilar competition in 2023. Patient Inconvenience: Biotech advancements have facilitated the development of effective biologic therapies; however, therapy administration requires frequent injections or infusions, making it challenging for patients to adhere to their treatment regimens. It may affect overall patient satisfaction and treatment discontinuation. The Impact of the Top 3 Strategic Imperatives on the Immunomodulator Therapeutics Industry Disruptive Technologies Why: There is an increasing incidence of autoimmune diseases, particularly impacting women. Limitations in existing therapies demand more targeted applications. Analyst Perspective: A new wave of drug classes (JAK1, IL, calcineurin, TNF?, TYK2, PDE4), across small molecules, biologics, and cell and gene therapies, will emerge, offering enhanced efficacy and safety profiles for treating autoimmune and inflammatory conditions. There will be a growing trend towards combination therapies that utilize multiple mechanisms of action to achieve better clinical outcomes. Internal Challenges Why: The industry is moving toward an extended patent cliff, with several revenue-generating blockbuster drugs like Humira and Stelara losing their exclusivity, leading to revenue losses and increased biosimilar competition, creating an urgent need for pipeline growth, and driving increased research and development (R&D). Resource demands for R&D can strain budgets, especially for smaller biotech firms. Analyst Perspective: Companies may increasingly seek strategic partnerships to share costs and risks, fostering innovation through collaborative R&D efforts. Companies that emphasize unique value propositions in these strategic alliances will be better positioned to access markets/fair pricing with drugs like JAK inhibitors and women-specific therapies. Payers will scrutinize clinical costs and patient outcomes to ensure balance and sustainable reimbursement models that reflect indication-specific needs and improve affordability. Transformative Megatrends Why: Healthcare systems are under pressure to contain current and future spending. Healthcare plan sponsors are considering their next moves as governments contemplate the impact of the Inflation Reduction Act (IRA) 2022, and associated price cuts in the United States. Analyst Perspective: Firms will invest in adaptive trial designs for evidence generation to expedite approvals for novel MoA-based targeted therapies, advancing precision medicine going forward. Pharma companies will utilize diagnostic delivery services to improve patient access by partnering with telehealth/AI-enabled symptom monitoring platforms (e.g., Ada Health) and focus on an emerging market-expansion strategy. Focus on predictive convergence of drugs and digital therapeutics will likely personalize medicine and improve experiences and outcomes. Scope of Analysis Ecosystem in the Immunomodulator Therapeutics Sector Growth Opportunity Universe in Immunomodulator Therapeutics Sector Key Competitors For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 07/04/2025 06:43 AM/DISC: 07/04/2025 06:43 AM
